In a new study published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, researchers sought to determine the percentage of COVID-19 patients discharged from the hospital who had a type of fibrotic lung damage, known as interstitial lung disease, that requires ongoing follow-up care. These patients had varying degrees of COVID-19 severity at hospital admission.
Tag: interstitial lung disease (ILD)
Prompt Recognition and Treatment Found Effective for Lung Disease in Patients Who Received New Drug for Advanced Cancer
Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.
Potential biomarker found for lung disease in scleroderma patients
Researchers have discovered a protein that may predict disease severity for scleroderma-associated interstitial lung disease, the leading cause of death for patients with the rare autoimmune condition. Higher circulating levels of the CTRP9 were associated with more severe lung disease, while low levels were associated with preserved function.
Dr. Anthony Shum Receives ATS Research Program/chILD Foundation Partner Grant
The ATS Research Program and the chILD Foundation have awarded Anthony Shum, MD, of the University of California, San Francisco $80,000. The award will support Dr. Shum’s research project, “Defining the pathogenesis of childhood ILD in COPA syndrome.”
Home Oxygen Therapy for Adults with COPD and ILD: New ATS Clinical Practice Guideline
The latest clinical practice guideline on home oxygen therapy addresses long-term and ambulatory oxygen therapy for adults with chronic obstructive pulmonary disease and interstitial lung disease and includes the most comprehensive review of the evidence of any oxygen guideline to date.